CD105 (CD105 Antigen, Endoglin, END, ENG, FLJ41744, HHT1, Osler-Rendu-Weber Syndrome 1, ORW1, ORW) (FITC)

Mutations in the gene encoding endoglin have been linked to the human disease hereditary hemorrhagic telangiectasia type 1 (HHT1) a vascular disorder characterized by localized vascular dysplasia and a tendency towards arteriovenous malformations. Mice expressing a single CD105 allele develop external signs of disease similar to human HHT1, supporting the haploinsufficiency model for HHT1. Mice lacking endoglin die from defective angiogenesis characterized by failure of vascular smooth muscle investment of embryonic blood vessels, suggesting a defect in vascular smooth muscle cell development. Microvessel density (MVD) has been reported to be an independent prognostic indicator of outcome in a variety of human malignancies, with increased MVD correlating with shorter overall and relapse-free survival rates. The MVD counts using anti-CD105 antibody significantly correlated with overall and disease-free survival. \n\nApplications: \nSuitable for use in Flow Cytometry. Other applications not tested.\n\nRecommended Dilution:\nFlow Cytometry: 20ul reagent/100ul sample.\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. FITC conjugates are sensitive to light.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts